BTK and B-cell chronic lymphocytic leukemia: Furthermore, ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, showed a decrease of the renal mass in a case study involving a 66-year-old male referred for a left renal mass along with newly diagnosed CLL.